ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Gastrointestinal Cancer

ASCO 2016 Genitourinary Cancers Symposium

Cancer Network presents exclusive coverage from the American Society of Clinical Oncology (ASCO) 2016 Genitourinary Cancers Symposium, held January 7–9 in San Francisco. We’ll bring you reports as we cover the latest research, trials, scientific advances, and controversies that are changing the way genitourinary cancers are managed and treated.

Gastrointestinal Cancer

High expression levels of EGFR ligands epiregulin and amphiregulin are associated with increased benefit from panitumumab in patients with RAS wildtype advanced colorectal cancer.

A combination of four biomarkers may be able to help clinicians identify patients who have a high-risk type of colorectal cancer.

Pancreatic cancer patients who received adjuvant therapy at a high-volume center had superior overall survival vs patients who were treated in a community setting.

Nanoliposomal irinotecan combined with fluorouracil/leucovorin improved overall survival in metastatic pancreatic cancer patients who have already been treated with gemcitabine.

A short-course of preoperative radiation therapy plus consolidated chemotherapy was shown to be as effective as standard preoperative chemoradiation in the treatment of locally advanced rectal cancer.

Everolimus improved progression-free survival by 6 to 8 months compared with placebo in patients with advanced neuroendocrine tumors of the gastrointestinal tract.

A novel drug, 177Lutetium-DOTATATE (Lutathera), significantly lowered the risk for disease progression or death among patients with previously treated, advanced midgut neuroendocrine tumors.

Pages

Subscribe to Gastrointestinal Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.